Correlation of Molecular Biomarkers With Biopsy Findings and Outcomes in Renal Transplant Recipients

University of California, Davis20 enrolled

Overview

This is a single-center, prospective, non-randomized, observational study to evaluate specific proteogenomic biomarker panels for acute rejection (AR) and chronic allograft nephropathy/interstitial fibrosis and tubular atrophy (CAN/IFTA) in blood, urine and kidney tissue (biopsy) in kidney transplant recipients. Proteogenomic profiles will be routinely monitored over one year after enrollment.

OBJECTIVE: The objective of this phase of the study is to allow the clinical site to gain familiarity with patient recruitment, sample and data collection, and interpretation of the proteogenomic biomarker report provided, through retrospective analysis. This phase of the study will provide a platform for the transplant physicians to gain confidence with the format, logistics, and potential use of the biomarker tests on blood and tissue.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Delayed Graft Function

Eligibility

Sex: ALLMin age: 18 YearsMax age: 82 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: Patients who meet all of the following criteria are eligible for enrollment as study participants: 1. Male and female recipients of all races, ≥18 years of age. 2. Patients undergoing primary or subsequent deceased-donor or living donor kidney transplantation. 3. Subject and/or guardian must be able to provide informed consent. 4. Subject and/or guardian must be able to comply with the study protocol. Exclusion Criteria: 1. Need for combined organ transplantation with an extra-renal organ and/or islet cell transplant. 2. Recipients of previous non-renal solid organ and/or islet cell transplantation 3. Infection with HIV. 4. Inability or unwillingness of a participant and/or guardian to provide informed consent \-

Locations (1)

University of California, Davis Transplant Center

Sacramento, California, United States

Outcomes

Primary Outcomes

Biopsy prove acute rejection

Incidence of acute rejection at the time of any kidney biopsy

Time frame: 12 months

Secondary Outcomes

Gene Expression Profiling

Blood and tissue collection from each subject at the time of each for cause or protocol kidney biopsy

Time frame: 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.